Pfizer Inc. (PFE) Reaches $36.22 Formed H&S; Orbimed Advisors Has Cut Clovis Oncology (Call) (CLVS) Holding By $99.15 Million

Pfizer Inc. (NYSE:PFE) Logo

Pfizer Inc. (PFE) formed H&S with $33.68 target or 7.00% below today’s $36.22 share price. Pfizer Inc. (PFE) has $211.87B valuation. The stock decreased 0.22% or $0.08 during the last trading session, reaching $36.22. About 15.21M shares traded. Pfizer Inc. (NYSE:PFE) has risen 10.95% since June 14, 2017 and is uptrending. It has underperformed by 1.62% the S&P500. Some Historical PFE News: ; 15/05/2018 – FDA Granted Approval of Retacrit to Hospira Inc., a Pfizer Company; 03/04/2018 – CNBC: Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price; 01/05/2018 – PFE SPLITTING COMPANY UP STILL OFF TABLE FOR FORSEEABLE FUTURE; 23/03/2018 – ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe; 25/04/2018 – Asklepios BioPharma: Pfizer Dosed First Patient in Its Mini-Dystrophin Gene Therapy Phase 1b Trial; 18/05/2018 – U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ; 03/04/2018 – Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price; 23/04/2018 – Pfizer hits stumbling block on Herceptin rival, but wins breakthrough status on MenB vaccine $PFE @BrittanyMeiling; 23/03/2018 – PFIZER INC – STUDY DID NOT MEET ITS PRIMARY ENDPOINT; 18/05/2018 – ASTRAZENECA PLC AZN.L – OFFSET BY EROSION OF CRESTOR SALES

Orbimed Advisors Llc decreased Clovis Oncology Inc (Call) (CLVS) stake by 96.7% reported in 2018Q1 SEC filing. Orbimed Advisors Llc sold 1.91 million shares as Clovis Oncology Inc (Call) (CLVS)’s stock declined 12.39%. The Orbimed Advisors Llc holds 65,000 shares with $3.43M value, down from 1.97M last quarter. Clovis Oncology Inc (Call) now has $2.37 billion valuation. The stock increased 7.06% or $2.97 during the last trading session, reaching $45.03. About 1.69 million shares traded or 32.66% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 11.65% since June 14, 2017 and is downtrending. It has underperformed by 24.22% the S&P500. Some Historical CLVS News: ; 15/05/2018 – Redmile Group LLC Exits Position in Clovis Oncology; 16/04/2018 – ASTRAZENECA PLC AZN.L – LYNPARZA TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL; 16/05/2018 – Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting; 10/04/2018 – CLOVIS ONCOLOGY – SEC’S ‘WELLS NOTICES’ ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934; 10/04/2018 – CLOVIS ONCOLOGY: SEC WANTS ADDED CLINICAL DATA ON ROCILETINIB; 06/04/2018 – CLVS CONFIRMS EXPANDED FDA LABEL FOR RUBRACA IN OVARIAN CANCER; 16/05/2018 – Clovis Oncology at Bank of America Conference Tomorrow; 08/03/2018 – CLVS NOTICE OF ALLOWANCE FOR RUCAPARIB HIGH DOSAGE STRENGTH; 23/03/2018 – CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets; 29/05/2018 – Clovis Oncology Announces European Commission Authorization of Rubraca® (rucaparib) for Women with Recurrent Ovarian Cancer

Among 23 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $40.14’s average target is 10.82% above currents $36.22 stock price. Pfizer had 80 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Monday, October 16. The firm has “Buy” rating given on Tuesday, October 31 by Piper Jaffray. On Thursday, April 7 the stock rating was reinitiated by JP Morgan with “Overweight”. Argus Research maintained Pfizer Inc. (NYSE:PFE) rating on Wednesday, July 29. Argus Research has “Buy” rating and $41 target. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Thursday, July 14. Cowen & Co maintained the stock with “Buy” rating in Monday, July 10 report. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Thursday, September 14 by Piper Jaffray. Credit Suisse maintained Pfizer Inc. (NYSE:PFE) rating on Wednesday, January 31. Credit Suisse has “Neutral” rating and $39 target. The firm has “Neutral” rating given on Friday, March 24 by Societe Generale. The firm has “Buy” rating given on Wednesday, October 28 by Deutsche Bank.

Investors sentiment decreased to 0.89 in 2018 Q1. Its down 0.17, from 1.06 in 2017Q4. It turned negative, as 70 investors sold Pfizer Inc. shares while 718 reduced holdings. 104 funds opened positions while 595 raised stakes. 4.01 billion shares or 1.39% less from 4.07 billion shares in 2017Q4 were reported. Marathon Capital owns 11,817 shares. Roffman Miller Inc Pa reported 0.06% in Pfizer Inc. (NYSE:PFE). Leisure Cap Mngmt invested in 1.35% or 43,369 shares. 1.06M are held by Gabelli Funds Lc. Rwc Asset Management Limited Liability Partnership reported 1.53% stake. Valmark Advisers reported 0.02% of its portfolio in Pfizer Inc. (NYSE:PFE). Cornerstone Capital reported 7,742 shares. Wheatland Advisors reported 41,049 shares. Budros Ruhlin & Roe reported 40,854 shares. Lucas Capital Mgmt accumulated 9,832 shares. Park National Corporation Oh holds 0.46% or 224,428 shares in its portfolio. British Columbia Mngmt has 0.76% invested in Pfizer Inc. (NYSE:PFE) for 2.82M shares. Archon Prns Ltd Liability holds 2.44% in Pfizer Inc. (NYSE:PFE) or 315,650 shares. Outfitter Advsr holds 6,250 shares. Pitcairn Communications owns 43,301 shares for 0.16% of their portfolio.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 7. They expect $0.75 earnings per share, up 11.94% or $0.08 from last year’s $0.67 per share. PFE’s profit will be $4.39B for 12.07 P/E if the $0.75 EPS becomes a reality. After $0.77 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -2.60% negative EPS growth.

Since December 15, 2017, it had 0 insider buys, and 13 insider sales for $18.09 million activity. Dolsten Mikael had sold 69,699 shares worth $2.55 million on Friday, March 9. JOHNSON RADY A also sold $998,666 worth of Pfizer Inc. (NYSE:PFE) on Tuesday, March 13. Another trade for 1,758 shares valued at $64,679 was made by CORNWELL W DON on Monday, February 26. 42,393 Pfizer Inc. (NYSE:PFE) shares with value of $1.52M were sold by HILL CHARLES H. MACKENZIE ALEXANDER R sold $249,750 worth of stock or 6,750 shares. LUND-JURGENSEN KIRSTEN sold $353,677 worth of Pfizer Inc. (NYSE:PFE) on Saturday, February 24. $4.76 million worth of Pfizer Inc. (NYSE:PFE) shares were sold by READ IAN C.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 65 analyst reports since September 10, 2015 according to SRatingsIntel. Barclays Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Tuesday, February 27 with “Overweight” rating. Piper Jaffray upgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Thursday, January 26 to “Overweight” rating. The rating was maintained by Oppenheimer on Monday, July 31 with “Hold”. On Monday, July 31 the stock rating was maintained by Leerink Swann with “Buy”. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Neutral” rating by Mizuho on Monday, November 16. The company was maintained on Thursday, November 2 by RBC Capital Markets. As per Wednesday, September 6, the company rating was maintained by J.P. Morgan. The firm has “Outperform” rating given on Thursday, February 22 by RBC Capital Markets. PiperJaffray upgraded the stock to “Overweight” rating in Thursday, January 26 report. WallachBeth Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, December 21 with “Hold” rating.

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Seekingalpha.com which released: “Clovis May 2018 Update” on May 16, 2018, also Nasdaq.com with their article: “Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today” published on June 04, 2018, Seekingalpha.com published: “Applied Materials Has Been Overly Punished – Cramer’s Lightning Round (5/29/18)” on May 30, 2018. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: Nasdaq.com and their article: “Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in …” published on June 04, 2018 as well as Seekingalpha.com‘s news article titled: “Clovis submits application to EMA to expand use of Rubraca to include maintenance treatment for women with …” with publication date: June 04, 2018.

Investors sentiment is 1.05 in Q1 2018. Its the same as in 2017Q4. It is flat, as 27 investors sold CLVS shares while 65 reduced holdings. only 27 funds opened positions while 70 raised stakes. 48.28 million shares or 1.64% less from 49.09 million shares in 2017Q4 were reported. Daiwa Gp holds 0% or 271 shares. Gam Ag invested in 21,800 shares or 0.04% of the stock. Millennium Management Limited Liability Co reported 248,377 shares. Los Angeles Cap Mgmt And Equity Incorporated invested in 0.01% or 35,824 shares. Cypress Capital Management Ltd Llc (Wy) owns 1,500 shares for 0.09% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,595 shares. Kazazian Asset Limited Liability Company invested 2.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Winslow Evans Crocker owns 2,300 shares or 0% of their US portfolio. Sg Americas Securities Limited Com holds 12,974 shares or 0.01% of its portfolio. Prudential Financial Incorporated has invested 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Tekla Cap Management has 0.15% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 75,400 shares. Federated Inc Pa has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Financial Bank Of New York Mellon invested in 0% or 255,459 shares. California State Teachers Retirement Systems holds 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 66,924 shares. Jennison Limited owns 697,576 shares or 0.04% of their US portfolio.

Orbimed Advisors Llc increased Sarepta Therapeutics Inc (NASDAQ:SRPT) stake by 271,600 shares to 321,600 valued at $23.83 million in 2018Q1. It also upped Insmed Inc (NASDAQ:INSM) stake by 1.43 million shares and now owns 2.93M shares. Shire Plc (NASDAQ:SHPG) was raised too.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart